Glucocorticoid Osteoporosis: A Need for Greater Awareness and Action

References

• Lukert B P, Raisz G L. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990; 112: 352–364
   PubMed Web of Science ®Google Scholar
• Wasnich R D, Benfante J, Yano K, et al. Thiazide effect on mineral content of bone. N Engl J Med 1983; 309: 344–347
   PubMed Web of Science ®Google Scholar
• Heidrich F E, Stergachis A, Gross K M. Diuretic drug use and the risk for hip fracture. Ann Intern Med 1991; 115: 1–6
   PubMed Web of Science ®Google Scholar
• Prior J C, Vigna Y M, Schecter M T, Burgess A E. Spinal bone loss and ovulatory disturbances. N Engl J Med 1990; 323: 1221–1227
   PubMed Web of Science ®Google Scholar
• Drinkwater B L, Nelson K, Chesnut C H, et al. Bone mineral content of amenorrheic and eumenorrheic athletes. N Engl J Med 1984; 311: 277–281
   PubMed Web of Science ®Google Scholar
• Drinkwater B L, Bruemner B, Chesnut C H. Menstrual history as a determinant of current bone density in young athletes. JAMA 1990; 263: 545–548
   PubMed Web of Science ®Google Scholar
• Prior J C, Vigna Y M, Schecter M T, Burgess A E. Spinal bone loss and ovulatory disturbances. N Engl J Med 1990; 323: 1221–1227
   PubMed Web of Science ®Google Scholar
• Greenspan S L, Oppenheim D S, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989; 110: 526–531
   PubMed Web of Science ®Google Scholar
• Finkelstein J S, Klibanski A, Neer R M, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69: 776–783
   PubMed Web of Science ®Google Scholar
• Finkelstein J S, Neer R M, Biller B MK, et al. Os-teopenia in men with a history of delayed puberty. N Engl J Med 1992; 326: 600–604
   PubMed Web of Science ®Google Scholar
• Reid I R, Veale A G, France J T. Glucocorticoid osteoporosis. J Asthma 1993; 31: 7–18
   Web of Science ®Google Scholar
• Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab 1975; 40: 774–779
   PubMed Web of Science ®Google Scholar
• Jackson J A, Kleerekoper M. Osteoporosis in men: Diagnosis, pathophysiology and prevention. Medicine 1990; 69: 137–152
   PubMed Web of Science ®Google Scholar
• Heaney R P. Thinking straight about calcium. N Engl J Med 1993; 328: 503–505
   PubMed Web of Science ®Google Scholar
• Hahn T J. Steroid and drug induced osteopenia. Chapter 5. Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism, M J Favus. American Society for Bone and Mineral Research, Kelseyville, CA 1990; 158–162, chapter 55
   Google Scholar
• Johnston C C, Slemenda C W, Melton L J. Clinical use of bone densitometry. N Engl J Med 1991; 324: 1105–1109
   PubMed Web of Science ®Google Scholar
• Adinoff A D, Hollister J R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309: 265–268
   PubMed Web of Science ®Google Scholar
• Reid I R, Evans M C, Wattic D J, et al. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporosis Int 1992; 2: 103–105
   PubMed Web of Science ®Google Scholar
• Reid I R, Heap S W. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990; 150: 2545–2548
   PubMedGoogle Scholar
• Gluck O S, Murphy W A, Hahn T J, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 1985; 24: 892–898
   Google Scholar
• Ross P D, Davis J W, Epstein R S, Wasnich R D. Preexisting fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114: 919–923
   PubMed Web of Science ®Google Scholar
• Greenspan S L, Greenspan F S, Resnick N M, et al. Skeletal integrity in premenopausal and postmeno-pausal women receiving long-term L-thyroxin therapy. Am J Med 1991; 92: 5–14
   Google Scholar
• Nelson H S, Corsello P R, Hamilos D L, et al. A double-blind study of troleandomycin and methyl-prednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 1993; 247: 398–404
   Google Scholar
• Erzurum S C, Leff J A, Cochran J E, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind placebo-controlled study. Ann Intern Med 1991; 114: 353–360
   PubMed Web of Science ®Google Scholar
• Toogood J H, Baskerville J, Jennings B, et al. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989; 84: 688–700
   PubMed Web of Science ®Google Scholar
• Hollister J R. The untoward effects of steroid treatment on the musculoskeletal system and what to do about them. J Asthma 1992; 29: 363–368
   PubMed Web of Science ®Google Scholar
• Wolthers O D, Pedersen S. Growth of asthmatic children during treatment with budesonide. A double blind trial. Brit Med J 1991; 303: 163–165
   PubMed Web of Science ®Google Scholar
• Lukert B P, Johnson B E, Robinson R G. Estrogen and progesterone replacement reduces glucocorticoid therapy-induced bone loss. J Bone Mineral Res 1992; 7: 1063–1069
   PubMed Web of Science ®Google Scholar
• Studd J WW, Savvas M, Johnson M. Correction of corticosteroid-induced osteoporosis by percutaneous hormone implants. Lancet 1989; 1: 339
   PubMed Web of Science ®Google Scholar
• Riggs B L, Hodgson S F, O'Fallon W M, et al. Effects of fluoride treatment on the fracture rate in post-menopausal women with osteoporosis. N Engl J Med 1990; 322: 802–809
   PubMed Web of Science ®Google Scholar
• Mamell N, Meunier P J, Dusan R, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988; 2: 361–365
   PubMed Web of Science ®Google Scholar
• Acute Leukemia Group B Eastern Cooperative Oncology Group. Ineffectiveness of fluoride therapy on multiple myeloma. N Engl J Med 1972; 286: 1283–1288
   PubMed Web of Science ®Google Scholar
• Inkovaara J, Heikinheimo R, Jarvinen K, et al. Prophylactic fluoride and aged bones. Br Med J 1975; 3: 73–74
   PubMedGoogle Scholar
• Riggs B L, Seeman E, Hodgson S F, et al. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in post-menopausal osteoporosis: Comparison with conventional therapy. N Engl J Med 1982; 306: 446–450
   PubMed Web of Science ®Google Scholar
• Dambacher M A, Ittner J, Ruegsegger P. Long-term fluoride therapy of postmenopausal osteoporosis. Bone 1986; 7: 199–205
   PubMed Web of Science ®Google Scholar
• Lindsay R. Fluoride and bone—Quantity versus quality. N Engl J Med 1990; 322: 845–846
   PubMed Web of Science ®Google Scholar
• Riggs L B, Melton L J. The prevention and treatment of osteoporosis. N Engl J Med 1992; 327: 620–627
   PubMed Web of Science ®Google Scholar
• Watts N B, Harris S T, Genant H K, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73–79
   PubMed Web of Science ®Google Scholar
• Gennari C, Agnudei D, Camporealle A. Use of cal-citonin in the treatment of bone pain associated with osteoporosis. Calcific Tissue Int 1991; 49(Suppl 2)S9–S13
   Google Scholar
• LoCacio V, Bonnucci E, Imbimbo B, et al. Bone loss after glucocorticoid therapy. Calcific Tissue Int 1984; 36: 435–438
   PubMed Web of Science ®Google Scholar
• Gennari C, Imbimbi B. Effects of prednisone and deflazacort on vertebral bone mass. Calcific Tissue 1985; 37: 592–593
   PubMed Web of Science ®Google Scholar
• Olgaard K, Storm T, Wowern N V, et al. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm and mandible of nephrotic patients. A double-blind study on the high-dose long-term effects of prednisone versus deflazacort. Calcific Tissue Int 1992; 50: 490–497
   PubMed Web of Science ®Google Scholar